70 unknown, 52 completed, 31 recruiting, 13 withdrawn. 77 Phase 2, 38 Phase 3, 13 Phase 1, 12 Phase 4, 8 Not applicable.
Follow Immune Thrombocytopenia: new trials by email Literature Review of Immune Thrombocytopenia trials Research Report on Immune Thrombocytopenia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Optimal Dose of Zanubrutinib to Treat Adult Immune Thrombocytopenia Zanubrutinib 80mg/d, High dose dexamethasone, Zanubrutinib 160mg/d - Immune Thrombocytopenia | Phase 2 | Not yet recruiting | Peking University People's Hospital | 90 | 2026-12-01 | 2026-11-12 |
| Selective Mediterranean Diet in Immune Thrombocytopenia Selective Mediterranean Diet, Standard Pharmacological Therapy for ITP - Immune Thrombocytopenia, Idiopathic Thrombocytopenic Purpura | Not applicable | Not yet recruiting | Assiut University | 60 | 2026-09-01 | 2026-09-03 |
| Eltrombopag Plus Telitacicept vs. Eltrombopag Alone for Steroid-refractory/Relapsed ITP Eltrombopag - Immune Thrombocytopenia | Phase 2 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 40 | 2026-07-10 | 2026-07-07 |
| A Real-world Study of Treatment Patterns and Outcomes in Primary Immune Thrombocytopenia Patients Treated With Eltrombopag Immune Thrombocytopenia | Recruiting | Novartis Pharmaceuticals | 150 | 2026-06-25 | 2026-10-15 | |
| Sirolimus in Patients With Systemic Lupus Erythematosus-Associated Immune Thrombocytopenia Sirolimus, Placebo - Systemic Lupus Erythematosus, Immune Thrombocytopenia | Phase 2 / Phase 3 | Recruiting | Chinese SLE Treatment And Research Group | 164 | 2026-06-07 | 2026-06-18 |
| ATRA for Management of Primary ITP all-trans retinoic acid (ATRA), Placebo - Immune Thrombocytopenia | Phase 3 | Not yet recruiting | Peking University People's Hospital | 192 | 2026-05-30 | 2026-05-19 |
| Universal STAR-T Cell Injection in R/R Autoimmune Diseases. Universal STAR-T Cell - Immune Thrombocytopenia | Phase 1 | Not yet recruiting | Jian Zhu | 6 | 2026-05-11 | 2026-05-20 |
| Safety and Efficacy of GL-2045 in Patients With Immune Thrombocytopenia GL-2045 - Immune Thrombocytopenia | Phase 1 | Recruiting | Gliknik Inc. | 42 | 2026-04-14 | 2026-05-26 |
| Daratumumab Versus Rituximab in the Management of Pediatric Primary Immune Thrombocytopenia (ITP) Rituximab, Daratumumab - Immune Thrombocytopenia, Treatment | Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 122 | 2026-03-01 | 2026-01-23 |
| Anti-CD38 Monoclonal Antibody Combined With Rituximab in the Management of Primary Immune Thrombocytopenia (ITP) Rituximab combined with Daratumumab（Anti-CD38 Monoclonal Antibody） - Immune Thrombocytopenia, Treatment | Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 20 | 2026-03-01 | 2026-01-23 |
| A Study of CD19 UCAR-T Cells in Subjects With Autoimmune Diseases CD19 UCAR-T cells - Systemic Lupus Erythematosus, Idiopahic Inflammatory Myopathies | Not applicable | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 24 | 2026-01-30 | 2025-12-19 |
| Rituximab Combining Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP) Daratumumab（Anti-CD38 Monoclonal Antibody）, Rituximab - Immune Thrombocytopenia, Treatment | Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 160 | 2026-01-28 | 2026-02-11 |
| Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP) Rituximab, Daratumumab - Immune Thrombocytopenia, Treatment | Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 160 | 2026-01-20 | 2026-02-11 |
| The Value of Interleukin-1β and Interleukin-33 Genetic Expression in the Pathogenesis and Differentiation of Primary ITP and SLE-Related Thrombocytopenia measuring gene expression - Immune Thrombocytopenia, System; Lupus Erythematosus | Not yet recruiting | Sohag University | 300 | 2026-01-01 | 2025-12-23 | |
| Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders INCA000585 - Immune Thrombocytopenia | Phase 2 | Recruiting | Incyte Corporation | 56 | 2025-12-29 | 2026-10-30 |
| Phase I Study of SHR-2173 Injection in Patients With Primary Immune Thrombocytopenia SHR-2173 Injection - Immune Thrombocytopenia | Phase 1 | Recruiting | Guangdong Hengrui Pharmaceutical Co., Ltd | 10 | 2025-11-12 | 2026-05-28 |
| Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line Treatment rilzabrutinib - Immune Thrombocytopenia | Phase 3 | Recruiting | Sanofi | 60 | 2025-10-24 | 2026-11-12 |
| Rilzabrutinib for the Adult Participants With Chronic ITP Who Have Completed Phase 3 Study in Japan rilzabrutinib - Immune Thrombocytopenia | Phase 3 | Active not recruiting | Sanofi | 3 | 2025-10-15 | 2026-11-10 |
| Anti-CD38 Antibody Treating Elderly Patients With Primary Immune Thrombocytopenia (ITP) Daratumumab Injection - Immune Thrombocytopenia, Treatment | Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 30 | 2025-08-01 | 2025-07-14 |
| The Combination of Upadacitinib and High-dose Dexamethasone as First-line Treatment in Adult Immune Thrombocytopenia Dexamethasone, Upadacitinib - Immune Thrombocytopenia | Phase 2 | Not yet recruiting | Peking University People's Hospital | 132 | 2025-07-30 | 2025-07-15 |
Showing 20 of 182. Sign in to see all of them.
Purpura, Thrombocytopenic, Idiopathic (182) · Thrombocytopenia (17) · Anemia, Hemolytic, Autoimmune (7) · Lupus Erythematosus, Systemic (6) · Blood Platelet Disorders (5) · Hematologic Diseases (4) · Purpura (4) · Purpura, Thrombocytopenic (4) · Purpura, Thrombotic Thrombocytopenic (4) · Blood Coagulation Disorders (3) · Evans Syndrome (3) · Hemorrhage (3) · Hemorrhagic Disorders (3) · Myelodysplastic Syndromes (3) · Anemia, Aplastic (2)
Cytopenia (182) · Hemic and Lymphatic Diseases (182) · Pathological Conditions, Signs and Symptoms (182) · Signs and Symptoms (182) · Pathologic Processes (181) · Autoimmune Diseases (180) · Immune System Diseases (180) · Skin Manifestations (180) · Thrombotic Microangiopathies (180) · Blood Coagulation Disorders (179) · Hemorrhage (179) · Hemorrhagic Disorders (179) · Hematologic Diseases (178) · Purpura (178) · Purpura, Thrombocytopenic (178)
Dexamethasone (26) · Rituximab (13) · eltrombopag (13) · Danazol (9) · romiplostim (9) · avatrombopag (8) · Immunoglobulins, Intravenous (7) · Inosine Triphosphate (5) · Thrombopoietin (5) · daratumumab (5) · zanubrutinib (5) · Blood Specimen Collection (4) · Prednisone (4) · Tretinoin (4) · Mycophenolic Acid (3)
Peking University People's Hospital (35) · Shandong University (29) · Institute of Hematology & Blood Diseases Hospital, China (19) · Assiut University (6) · Weill Medical College of Cornell University (5) · Assistance Publique - Hôpitaux de Paris (4) · Sobi, Inc. (4) · University Hospital, Bordeaux (4) · Gruppo Italiano Malattie EMatologiche dell'Adulto (3) · Jiangsu HengRui Medicine Co., Ltd. (3) · Sohag University (3) · Amgen (2) · Baylor College of Medicine (2) · Boston Children's Hospital (2) · Henri Mondor University Hospital (2)
China (90) · United States (27) · France (18) · United Kingdom (12) · Italy (10) · Spain (10) · Australia (9) · Germany (8) · Canada (7) · Poland (7) · Czechia (6) · Norway (6) · South Korea (6) · Egypt (5) · Hungary (5)
Xiao-Hui Zhang, MD (11) · Lei Zhang, MD (10) · Xiaohui Zhang, MD (6) · Ming Hou (5) · Ming Hou, Dr (5) · Ming Hou, MD, PhD (3) · Ming Hou, MD,PhD (3) · Jong Wook Lee, MD (2) · Lei Zhang, M.D. (2) · Ming Hou, Dr. (2) · Ming Hou, MD PhD (2) · Xiao-hui Zhang, Professor (2)
PMID 23470153, PMID 24254965, PMID 24802773, PMID 19005182, PMID 20546023, PMID 21674758, PMID 21710166, PMID 23293082, PMID 23445876, PMID 23616916, PMID 25132654, PMID 25247485, PMID 25566808, PMID 25618218, PMID 25830126, PMID 26480931, PMID 26709028, PMID 26831482, PMID 27040278, PMID 27103127, PMID 27281793, PMID 27307776, PMID 28630121, PMID 29659042, PMID 29736158, PMID 30191972, PMID 30341143, PMID 30945320, PMID 31591739, PMID 32817288, PMID 34386974, PMID 34452956, PMID 34469646, PMID 34560012, PMID 34665865, PMID 34922648, PMID 35049070, PMID 35417637, PMID 35643952, PMID 36448274, PMID 37601010, PMID 37735543, PMID 37823469, PMID 37833799, PMID 37869360, PMID 38013593, PMID 38029356, PMID 38227934, PMID 38386978, PMID 38899695
2023 (3), 2014 (1), 2017 (1), 2018 (1), 2025 (1)